

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 35/34, 35/14, 38/48, A01N 63/00, A61F 13/00, C12N 9/74, 5/00, 5/02, 5/06, 5/16	A1	(11) International Publication Number: WO 99/22747 (43) International Publication Date: 14 May 1999 (14.05.99)
(21) International Application Number: PCT/US98/23015 (22) International Filing Date: 29 October 1998 (29.10.98) (30) Priority Data: 60/064,451 30 October 1997 (30.10.97) US (71) Applicant: THE GENERAL HOSPITAL CORPORATION [US/US]; 55 Fruit Street, Boston, MA 02114 (US). (72) Inventors: ZALESKE, David, J.; 94 Oak Street, Weston, MA 02193 (US). PERETTI, Giuseppe; Via Gubbio, 10, I-20122 Milan (IT). CARUSO, Enzo; Via Wittgens, 5, I-20123 Milan (IT). ROSSETTI, Francesco; Via Garofalo, 32, I-20133 Milan (IT). RANDOLPH, Mark; 37 Longmeadow Road, Chelmsford, MA 01824 (US). (74) Agent: CREASON, Gary, L.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: BONDING OF CARTILAGINOUS MATRICES USING ISOLATED CHONDROCYTES (57) Abstract Methods of bonding cartilage pieces using new cartilage matrix generated by isolated chondrocytes in the presence of a biological gel. Also featured in the invention are cartilage implants used to repair cartilage defects.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

WO 99/22747

PCT/US98/23015

- 1 -

BONDING OF CARTILAGINOUS
MATRICES USING ISOLATED CHONDROCYTES

Field of the Invention

5 The field of the invention is cartilage repair.

Statement as to Federally Funded Research

 This invention was made with government support
under National Institutes of Health Grant AR31068.

Background of the Invention

10 Cartilage, which is a heterogeneous tissue, can be
classified as either articular or epiphyseal/physeal.
Disturbances in cartilage structure and function are seen
in congenital, infectious, traumatic, degenerative and
neoplastic conditions. Biological repair of focal
15 articular cartilage defects has generated great interest,
yet some of the variables of this process have not been
precisely defined (see, e.g., Brittberg et al., *New Engl.
J. Med.*, 331:889-895, 1994; and Mankin, *New Engl. J.
Med.*, 331:940-941, 1994). Such variables include the
20 biochemical and biomechanical properties of the repair
tissue itself and also its bonding with adjacent
cartilage and bone.

 The morphogenetic scaffold to which chondrocytes
may attach and form matrix is one of the variables that
25 have effects on the repair tissue. Materials that have
been used as the scaffold include collagen gel (Fujisato
et al., *Biomaterials*, 17:155-162, 1995; Hansen et al.,
Clin. Orthop., 256:286-298, 1990; Mizuno et al., *Exp.
Cell. Res.*, 227:89-97, 1996; Nixon et al., *Am. J. Vet.
30 Res.*, 54:349-356, 1993; Sams et al., *Osteoarthr. Cartil.*,
3:47-59, 1995; Sams et al., *Osteoarthr. Cartil.*, 3:61-70,
1995), fibrin glue (Hendrickson et al., *J. Orthop. Res.*,
12:485-497, 1994; Homminga et al., *Acta Orthopedica
Scandinavica*, 64:441-445, 1993; Tsai et al., *J. Formosan*

WO 99/22747

PCT/US98/23015

- 2 -

- Med. Assoc., 3(Suppl):239-245, 1993), polyglycolic acid (Freed et al., *Biotechnology*, 12:689-693, 1994; Vacanti et al., *Am. J. Sports Med.*, 22:485-488, 1994), polyethylene oxide gel (Sims et al., *Plast. Reconstr. Surgery*, 98:843-850, 1996), alginate gel (Van Susante et al., *Acta Orthopédica Scandinavica*, 66:549-556, 1995), carbon fiber pads (Brittberg et al., *Clin. Orthop.*, 326:270-283, 1996) and xenogeneic matrix (Caruso et al., *J. Orthop. Res.*, 14:102-107, 1996).
- 10 Isolated and cultured chondrocytes embedded in these various scaffolds have been used for filling and repairing articular cartilage defects in chicks (Itay et al., *Clin. Orthop.*, 220:284-303, 1987), rabbits (Grande et al., *Anatomical Records*, 218:142-148, 1987; Grande et al., *J. Orthop. Res.*, 7:208-218, 1989; Wakitani et al., *J. Bone Joint Surg. [Br.]*, 71:74-80, 1989), dogs (Shortkroff et al., *Biomaterials*, 17:147-154, 1996), and horses (Hendrickson et al., *supra*; Sams et al., *Osteoarthr. Cartil.*, 3:47-59, 1995; Sams et al., *Osteoarthr. Cartil.*, 3:61-70, 1995).
- 20 Complete repair of partial defects of cartilage implies side-to-side joining of cartilaginous matrices. While such joining has been investigated in several ways (Hunziker et al., *Trans. Orthop. Res. Soc.*, 17:231, 1992; Reindel et al., *J. Orthop. Res.*, 13:751-760, 1995; Wolohan et al., *J. Orthop. Res.*, 9:180-185, 1991), options for accomplishing this still need to be expanded.

Summary of the Invention

- 30 The present invention is based on the discovery that isolated chondrocytes can propagate in the presence of an appropriate biological gel (e.g., fibrin gel) and generate cartilage matrix that firmly bonds two adjacent cartilage pieces.

WO 99/22747

PCT/US98/23015

- 3 -

Accordingly, the invention features a method of bonding two cartilage pieces. In this method, a bonding composition containing isolated chondrocytes mixed with a biological gel is applied to a surface of one (or both) of the cartilage pieces, and the surface is then contacted with the other cartilage piece. New cartilage matrix generated by the bonding composition will provide durable (e.g., 1% or more of normal cartilage strength) bonding between the two contacting cartilage pieces. The order of steps in the above-described method can be altered. For instance, the two cartilage pieces to be bonded can be held in apposition, and then the bonding composition is applied to fill gaps at the interface of the two cartilage pieces.

In another method of the present invention, either or both of the cartilage pieces are first incubated with isolated chondrocytes. A biological gel is then applied to a surface of either or both of the two pieces, and the two pieces are held together at the surface. Alternatively, the two cartilage pieces to be bonded can be held in apposition first to form a cartilage composite; after the composite is incubated with isolated chondrocytes, a biological gel is applied to fill gaps at the interface of the two cartilage pieces.

Isolated chondrocytes are chondrocytes that are separated from cartilage matrix, and they can be obtained from cartilage tissue or bone marrow. Both freshly isolated and cultured chondrocytes can be used.

A biological gel is a flexible, biodegradable (i.e., bioresorbable) and biocompatible (i.e., has no or negligible *in vivo* toxicity and is compatible with *in vivo* conditions) composition that typically has pores large enough to allow chondrocytes to populate. An exemplary biological gel is fibrin gel (also called fibrin glue). Fibrin gel has been used as the basis of many biological glues or adhesive matrices, and can be prepared with

WO 99/22747

PCT/US98/23015

- 4 -

coagulation factors including thrombin and fibrinogen. Fibrinogen is cleaved by thrombin to form fibrin at the initiation of clotting.

One or both of the cartilage pieces to be bonded
5 can be depleted of endogenous (i.e., innate) chondrocytes before the isolated chondrocytes are applied. The cartilage pieces to be bonded can be articular cartilage, fibrocartilage or growth cartilage, and can be obtained from the patient to be treated, or from a donor of the same or
10 different species.

The new methods can be used to repair (i.e., resurface), in a mammal (e.g., human, mouse, rat, dog, horse, lamb, sheep, etc.), articular cartilage having a defect (e.g., a partial or full thickness defect); in that
15 case, one of the two pieces to be bonded is the defective cartilage, and the other piece constitutes a part of a cartilage implant, and the chondrocytes used can be derived from the mammal itself. The present methods can also be used to treat defects in other types of cartilage, e.g., a
20 meniscal tear in fibrocartilage or a resection defect resulting from excision of a physeal bar from an injured growth plate.

Also featured in the invention is a method of preparing a cartilage implant. In this method, a
25 cartilage piece (e.g., one that contains no or essentially no viable endogenous chondrocytes) of appropriate size and shape is first co-cultured with isolated chondrocytes, and then a biological gel is applied to the cartilage piece to generate an implant.
30 Alternatively, a bonding composition as described above can be applied directly the cartilage piece to generate an implant.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as
35 commonly understood by one of ordinary skill in the art

WO 99/22747

PCT/US98/23015

- 5 -

to which this invention belongs. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. The materials, methods, and examples described herein are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

Brief Description of the Drawings

Figs. 1A and 1B are graphs showing applied tensile displacement and measured tensile load, respectively, from an experimental cartilage composite seeded with isolated chondrocytes and implanted in vivo for 21 days.

Fig. 1C is a graph showing a stress-strain curve generated from data shown in Figs. 1A and 1B by normalizing displacement data to measured sample thickness and load data to sample area. S_{UTS} stands for ultimate tensile strength, ϵ_f for fracture strain, M for dynamic tensile modulus, and E_f for fracture energy.

Figs. 2A-2D are graphs showing the time course of changes in tensile strength, fracture strain, fracture energy, and tensile modulus, respectively, of experimental and control cartilage composites. The composites were implanted in nude mice for the time period indicated on the horizontal axis. All data are shown as mean \pm SD, with the number of data points at each time point ranging from 4 to 6 for experimental composites and 2 to 4 for controls. In each of the four

WO 99/22747

PCT/US98/23015

- 6 -

figures, "*" denotes appropriate p value for significance of difference between the experimental group and the control group at that time point.

Detailed Description of the Invention

5 The methods of the invention are useful for bonding two or more cartilage pieces. In one of these methods, one first obtains a bonding composition comprising isolated chondrocytes mixed with a biological gel (e.g., about 10^5 to 10^7 cells/per ml gel), and then
10 applies the bonding composition to the interface of the two cartilage pieces. Alternatively, one can first co-culture one or both of the cartilage pieces (e.g., devitalized pieces) with isolated chondrocytes (at a concentration of about 10^5 to 10^7 cells/per ml medium),
15 and then apply a biological gel to the interface of the pieces. The chondrocytes that have infiltrated the cartilage pieces will then migrate into the gel.

 The biological gel serves as a biodegradable and biocompatible scaffold on which the chondrocytes will
20 proliferate and generate durable cartilage matrix. Biological gels that may be used include, but are not limited to, collagen gel, fibrin glue, polyglycolic acid, polylactic acid, polyethylene oxide gel, alginate or calcium alginate gel, poly-(2-hydroxyethyl methacrylate)
25 (i.e., a hydrogel), polyorthoester, hyaluronic acid, polyanhydride, gelatin, agarose, and other bioresorbable and biocompatible materials such as those described in EP 0705878 A2. To promote chondrocyte proliferation and function, the biological gel can additionally contain
30 appropriate nutrients (e.g., serum, salts such as calcium chloride, ascorbic acid, and amino acids) and growth factors (e.g., somatomedin, basic fibroblast growth factor, transforming growth factor β , cartilage growth factor, bone-derived growth factor, or a combination

WO 99/22747

PCT/US98/23015

- 7 -

thereof). Selection of the optimal biological gel can be made using the guidance provided in the Examples below.

Chondrocytes useful in the new methods can be isolated from, e.g., articular cartilage or epiphyseal growth-plate, by digestion with collagenase and optionally trypsin. Mesenchymal cells obtained from bone marrow can also be differentiated into chondrocytes under appropriate culture conditions as described by, e.g., Butnariu-Ephrat et al., *Clinical Orthopaedics and Related Research*, 330:234-243, 1996. Other sources from which chondrocytes can be derived include dermal cells and pluripotent stem cells. The methods of the invention can be used to repair defective articular cartilage. To do so, a cartilage piece cut into the shape and size of a defect (see, e.g., Chu et al., *Arch. Am. Acad. Orthop. Surg.*, 1:9-14, 1997) is press-fitted and bonded to the defect. The cartilage implant can be, for example, autogeneic, isogeneic (e.g., from an identical twin), allogeneic, or xenogeneic. Before new cartilage matrix is generated at the interface of the implant and the host bed, resulting in a durable bonding between the implant and the host bed, the implant can be held in place by, e.g., bioresorbable pins (see, e.g., Chu et al., *supra*), or a piece of periosteal/perichondrial tissue sutured over the site of implantation (see, e.g., Minas et al., *Orthopedics*, 20:525-538, 1997; and WO 97/30662). One can also select an adhesive biological gel (e.g., fibrin gel) that provides temporary adhesion between the two cartilage pieces. The chondrocytes used for repairing cartilage defects can be, e.g., autogeneic, isogeneic, or allogeneic. Before implantation, the host cartilage to be repaired can be treated with, e.g., an enzyme, to remove proteoglycans and other substances that may interfere with the bonding.

WO 99/22747

PCT/US98/23015

- 8 -

The following examples are meant to illustrate the methods and materials of the present invention. Suitable modifications and adaptations of the variety of conditions and parameters normally encountered in bonding cartilaginous matrices which are obvious to those skilled in the art are within the spirit and scope of the present invention.

EXAMPLE I: Preparation of Cartilage Implant

MATERIALS AND METHODS

10 *Chondrocyte Isolation*

Articular cartilage was harvested from lamb hips and shoulders by removing the superficial layers of articular cartilage under sterile conditions. The subchondral bone was avoided. Cartilage pieces were incubated for 8 hours at 37°C in HAM's medium with Glutamax-1 (GibcoBRL, Grand Island, NY) containing 0.075% collagenase Type 2 (Worthington Biochemical Co. Freehold, NJ), 10% fetal bovine serum (Sigma, St. Louis, MO), 50 µg/ml ascorbic acid, 1% antibiotic/antimycotic solution (Sigma; each ml of the solution contains 10,000 units Penicillin, 10 mg Streptomycin, and 25 µg Amphotericin B in 0.9% NaCl), and L-glutamine 292 mg/l. Subsequent to the incubation, undigested tissue and debris were removed by filtering the cell suspension through a sterile nylon gauze.

Processing of Allogeneic Matrix

Slices of articular cartilage, each measuring approximately 3 millimeters ("mm") in width, 5 mm in length, and 1 mm in thickness, were harvested from knees and shoulders of unrelated lambs under sterile conditions. They were then placed in 50 ml test tubes containing phosphate buffered saline ("PBS") and 2% of the antibiotic/antimycotic solution (Sigma) and frozen at minus 20°C for five days. After thawing, the PBS solution

WO 99/22747

PCT/US98/23015

- 9 -

was discarded and the cartilage slices were subjected to five cycles of freezing and thawing in the absence of PBS.

Next, chondrocyte viability was evaluated in 5 exemplary pieces by Trypan blue staining (Trypan blue 0.2%, Sigma) and fluorescence microscopy as previously described (Vacanti et al., supra). This procedure revealed that the cyclic freezing and thawing had killed all the innate chondrocytes in the cartilage slices. 10 Cartilage slices with no detectable chondrocytes were termed "non-viable cartilage matrix" or "devitalized cartilage matrix."

Co-Culturing of Chondrocytes with Allogeneic Matrix

The cell suspension obtained as described above 15 was centrifuged at 4000 rpm for ten minutes, and washed in PBS containing 2% of the antibiotic/antimycotic solution. Viability of chondrocytes was assessed by Trypan blue staining and recorded as a percentage of viable chondrocytes per high power field. Only those 20 chondrocyte cultures having a viability score of 90% or greater were used in further studies described below. The exact cell count per ml was established using a hemocytometer. Chondrocyte solutions were adjusted to a concentration of 10^6 cells/ml prior to use.

25 Co-culturing of chondrocytes with allogeneic matrix was performed by placing three slices of non-viable cartilage matrix in a 12 ml test tube (Corning, NY, USA) containing 4 ml of F12 medium (Sigma) and 1 ml of the adjusted chondrocyte solution. The cartilage 30 slices and the chondrocytes were co-cultured in the F12 medium for 21 days. Control samples that contained no chondrocytes were kept under the same culture condition. In all cultures, the medium was changed twice weekly. For experimental groups, the fresh medium contained 10^6 35 chondrocytes/ml.

WO 99/22747

PCT/US98/23015

- 10 -

Preparation of Matrix Composites

After co-culturing, the three cartilage slices infiltrated with chondrocytes (i.e., experimental slices) were removed from the media. This was done by placing
5 the test tube on a vortex machine to re-suspend chondrocytes that were only loosely attached to the cartilage slices. The medium was then removed by aspiration, and the cartilage slices were re-suspended in fresh medium.

10 After this washing procedure was repeated several times, the three cartilage slices were placed onto a sterile Petri dish, and stacked on a sterile 27 gauge insulin needle by piercing each one through the center. Then, fibrin glue gel made from human cryoprecipitate and
15 bovine thrombin (USP-Thrombostat, Parke Davis Lambert Co, Morris Plains, NJ) was applied around the three slices to form a composite cartilage unit. The fibrin glue set in a few minutes, and the needle was subsequently removed.

20 Control composites were made with non-viable cartilage slices that had not been co-cultured with isolated chondrocytes.

Animal Model

Implantation of experimental and control matrix
25 composites was performed under sterile conditions in a laminar flow hood. The composites were implanted into subcutaneous pouches at four sites in the backs of nude mice. Two experimental and two control composites were implanted in each animal. After sacrifice of the
30 animals, cartilage composites were recovered under sterile conditions and evaluated as described below.

Evaluation of Composites Recovered from Mice

As shown in Table 1, three separate animal groups were employed for three different studies.

WO 99/22747

PCT/US98/23015

- 11 -

The first group, which consisted of 4 mice (each with four composites), was used to assess the bonding and histology of the matrix composites at various times (i.e., at 7, 14, 21, 28 and 42 days following implantation). The composites were examined with a pair of jeweler's forceps for the existence of fusion at the contact planes between the adjacent cartilage slices and separatability of the slices by the forceps' opening force. Each composite of three cartilage slices had two contact planes. The data on bonding between the cartilage slices presented below and in Table 2 refer to the 16 contact planes in the 8 experimental cartilage composites and to the 16 contact planes in the 8 control cartilage composites for each time period. A rank order scale was used to record the bonding between the cartilage slices. When the cartilage slices were completely fused with one another at their contact planes, a value of one was assigned. When any separation at all between slices was produced by the forceps, a value of zero was assigned. Bonding was expressed in absolute numbers and percentages per group. Composites used for histological analysis were fixed in 10% phosphate buffered formalin, embedded in paraffin, sectioned at five micrometers, stained with Safranin-O, and examined under a light microscope at 200X or 400X.

WO 99/22747

PCT/US98/23015

- 12 -

Table 1.

Study group		Time periods:	Day 0 (not implanted)	Day 7	Day 14	Day 21	Day 28	Day 42	Totals
5	Number of implants for surfaces bonding evaluation and histologic analysis	Experimental	8	8 [4]	8 [4]	8 [4]	8 [4]	8 [4]	48 [20]
		Control	8	8	8	8	8	8	48
10	Number of implants for [³ H]Thymidine incorporation analysis	Experimental	8	-	8 [4]	-	8 [4]	8 [4]	32 [12]
		Control	8	-	8	-	8	8	32
15	Number of implants for fluorescence microscopy evaluation	Experimental	8	-	8 [4]	-	8 [4]	8 [4]	32 [12]
		Control	8	-	8	-	8	8	32
Totals:		Experimental	24	8 [4]	24 [12]	8 [4]	24 [12]	24 [12]	88 [44]
		Control	24	8	24	8	24	24	88

20 The number of nude mice used are recorded in brackets []. The composites were inserted into subcutaneous pouches on the back of the mouse at four different sites. Two experimental and two control composites were randomly assigned to and implanted in the two cranial and two caudal sites.

WO 99/22747

PCT/US98/23015

- 13 -

Table 2.

DAY	Experimental group Bonding	Control group Bonding
0	0/16 (0%)	0/16 (0%)
7	0/16 (0%)	0/16 (0%)
14	4/16 (25%)	0/16 (0%)
21	12/16 (75%)	0/16 (0%)
28	16/16 (100%)	0/16 (0%)
42	16/16 (100%)	0/16 (0%)

The second group, which consisted of 12 mice (each with four composites), was divided evenly into 3 subgroups for evaluating chondrocyte division at 14, 28, and 42 days, respectively, following implantation surgery. To evaluate chondrocyte division, each recovered composite was incubated with 16 $\mu\text{Ci/ml}$ of [^3H]thymidine for 24 hours in an atmosphere of 92% air and 8% CO_2 . Each composite was then hydrolyzed and combined with 3 ml of CYTOSCINT[™] (ICN, Costa Mesa, CA). Radioactivity counts released from the composite were determined with a BECKMAN LS5000TD β -scintillation counter (Beckman, Fullerton, CA).

The third animal group consisted of 12 mice as well, and was used to evaluate composites recovered therefrom by fluorescence microscopy. Fifteen 100 μm thick sections of experimental and control cartilage composites were prepared using a 752M VIBROSLICE[™] microtome (Campden Instruments LTD, Loughborough, England). These sections were then incubated with 100 μl of fluorescent dye solution (consisting of 3 μl calcein AM and 8 μl ethidium homodimer in 5 ml PBS; Molecular Probes, Eugene, OR) for 1 hour. Cell viability within the matrix of experimental and control cartilage

WO 99/22747

PCT/US98/23015

-14-

composite units was assessed on fresh 100 μ m thick sections using a fluorescent microscope (Nikon MICROPHOT-FX™, Garden City, NY). The calcein is taken up by viable cells and strongly fluoresces green, which is seen as a region of high light intensity on black and white photographs. The ethidium homodimer passively enters non-viable cells and weakly fluoresces red, which is seen as a region of low light intensity on black and white photographs.

Baseline values on composites prior to implantation were obtained for bonding (0/16), histology, [³H]thymidine incorporation and fluorescence.

Statistical Analysis

Unpaired Student's t tests were used to compare [³H]thymidine incorporation values (mean \pm SD) collected throughout the time periods examined. The Bonferroni modification was employed to maintain a type I error rate of 0.05 across all comparisons. In addition, experimental and control values during each session of the study were compared by means of unpaired Student's t tests ($p < 0.05$).

RESULTS

Starting at day 7 after implantation, fibrous capsules were formed by the fibrin glue previously applied to hold the pieces together, and they thickened with time. The capsules were removed for evaluation of bonding. The bonding of the experimental matrices infiltrated with viable chondrocytes increased with time until all such specimens were united at approximately days 28 to 42. Macroscopic view of the experimental composites at 42 days following implantation revealed that, while the original slices of matrix were discernible, the composite had united into a solid cartilaginous mass. However, at all time points examined, the cartilage pieces in the control composites slid apart spontaneously and immediately after the removal of the fibrous capsule. Thus, the distinction between success and failure in bonding was easy to discern.

Histological evaluation showed that, prior to implantation, the experimental composites had live

WO 99/22747

PCT/US98/23015

- 15 -

chondrocytes on the surface of their devitalized cartilage slices, whereas only some nuclear debris of dead cells but no vital cells were found in control composites.

Microscopic examination of cartilage composites

5 recovered after implantation revealed that chondrocytes were forming matrix at the contact planes between the allogeneic slices of experimental composites, and that this new cartilage layer increased in thickness from day 7 to day 42. At day 7 after implantation, viable chondrocytes forming
10 matrix were seen on the contacting surfaces of cartilage slices, and the fibrin glue formed a relatively thick layer between the contact surfaces. At day 14, each layer of viable chondrocytes had increased in thickness, and the fibrin glue layer had shrunk. By day 21, the contact space
15 between the elliptically shaped allogeneic matrices was filled with viable chondrocytes making new matrix, and the fibrin glue had been mostly absorbed. 28 days following implantation, the entire contacting region between adjacent cartilage slices was filled with new cartilage. Buds of new
20 cartilage started to grow into the devitalized matrices. At day 42, more ingrowth of the buds, some of which had branches, was seen, and loss of Safranin-O staining of the devitalized matrix occurred around the new cartilage, indicating that matrix-generating chondrocytes were invading
25 the devitalized matrix. By this time, new cartilage, the organization of which grossly resembled that of mature cartilage, had entirely filled the holes in the cartilage slices created by the needle used during composite assembly with fibrin glue. Safranin-O staining in the new cartilage
30 had also increased. Several mitotic figures were encountered in the new cartilage layer at every time period.

The control composites, on the other hand, showed no new matrix formation at any time point examined. Sectioning of these composites could be accomplished only because of
35 the surrounding fibrous capsule. The capsule stained only

WO 99/22747

PCT/US98/23015

- 16 -

with the Fast Green counter-stain and not Safranin-O. No viable chondrocytes were found present.

Examination of chondrocyte division showed a statistically significant decrease in [³H]thymidine incorporation into the experimental composites from day 0 (about 85,000 counts per minute or cpm) to day 28 (about 10,000 cpm), followed by an increase at day 42 (about 43,000 cpm). The differences at the various time points for the experimental composites were significant, with p less than 0.01 in Student' t test. Incorporation of [³H]thymidine into control composites was not significantly different from baseline (about 2,000 cpm) at any time period. The differences between the experimental and control groups were significant (p < 0.05) at each time point examined (i.e., days 0, 14, 28, and 42).

Examination of the experimental composites with fluorescence microscopy (at 100X) confirmed that the growth of the new matrix was occurring with a concomitant increase in viable chondrocytes interstitially. Fluorescence staining of experimental composites at day 42 revealed that the devitalized matrices did not take up calcein, whereas the new cartilage layer formed between neighboring matrices fluoresced brightly with calcein, indicating the presence of viable cells in the layer. Buds of new cartilage that fluoresced brightly with calcein were also seen penetrating the devitalized matrix. Viable clusters of chondrocytes were seen within the allogeneic matrices at days 28 and 42.

Example II: Biomechanical Assessment of Cartilage Bonding

To test the strength of the bonding formed between two cartilage disks as described in the above Example, the pair of bonded disks were glued onto plexiglass rods and mounted in the jaws of a testing machine. The bonded slices were pulled to failure in tension as indicated by either visible separation of cartilage disks or when the measured load was

WO 99/22747

PCT/US98/23015

- 17 -

observed to be less than 0.05 Newton. Resultant loads were recorded on a personal computer, and data were collected at a rate of 5 points/second. Sample pairs were kept hydrated with PBS throughout testing.

5 Applied displacements and measured loads were normalized to sample thickness and area, and using these data, a stress-strain curve was constructed for each sample. From the stress-strain curve, the ultimate tensile strength (S_{UTS}) was determined by inspection as the strain at which
10 further increases in strain produced lower stresses. The fracture strain (ϵ_f) was also determined by inspection. The fracture energy (E_f), defined as the area under the stress-strain curve until failure, was calculated numerically using a Reimann sum method with the partition element given by the
15 strain interval between data points. The dynamic tensile modulus (M) for the given strain rate of each sample was calculated as the slope of the linear portion of the stress-strain curve using a standard least squares algorithm.

Cartilage composites implanted in nude mice as
20 described in Example I were retrieved at a weekly interval for up to 6 weeks. Tensile strength, fracture strain, fracture energy, and tensile modulus of the cartilage bonding formed in these composites were assessed. The values of these parameters are indicative of bonding
25 strength. Data shown in Figs. 2A-2D demonstrated that the values of the four parameters were significantly higher in cartilage composites containing isolated chondrocytes than in composites not containing chondrocytes. The values also increased steadily with time in the former composites, and
30 by week 6, reached 5-10% of the corresponding values of normal articular cartilage.

After biomechanical tests, samples were retrieved for histological evaluation. Histological evaluation was also performed on a few samples that were not biomechanically
35 tested. For pre- and post-test histological analysis,

WO 99/22747

PCT/US98/23015

- 18 -

specimens were fixed in 10% phosphate buffered formalin and embedded in paraffin. Serial sections that were 5 μ M thick were obtained and stained with Safranin-O.

Histological analysis of biomechanically tested samples indicated that failure of bonding occurred at the interface between the new and devitalized cartilage in experimental groups or between the two discs of cartilage for controls. After the two layer of new matrix fused at about day 21, failure was never observed in the thickness of the new tissue, but always at the interface of the newly formed matrix and the devitalized cartilage.

In samples fixed during testing, newly formed tissue was pulled away from devitalized cartilage matrix. This was analogous to an apparent crack propagating along the interface between new and devitalized matrix. Observation of this process revealed that, in vicinity of the crack tip, cells along the fracture line appeared to be elongated in the direction perpendicular to the line of crack propagation. Occasionally, fractures occurred in opposite sides and both propagated towards the center, leaving an intact connection.

In case where chondrocytes penetrated devitalized matrix, fracture occurred at the opposing interface in 80% of the sections sampled.

As shown above, the strength of the interface between the new tissue and existing matrix increases with time, demonstrating remodelling of the new tissue, even after the space between the pieces of matrix has been filled with new tissue. Although the total fusion of the two layers of new matrix occurred at about day 21, as shown by the histology, the biomechanical study showed an increase of the strength of the repair tissue at further evaluation times (days 28 and 42). This phenomenon could be explained by the formation of buds of penetration from the new tissue into the devitalized matrix, stabilizing the construct and making

WO 99/22747

PCT/US98/23015

- 19 -

the interface stronger; this is consistent with histological finding that in 80% of sections sampled, failure occurred on the opposite interface when penetration were present.

Example III: Meniscus Repair

5 This example applies the cartilage repair procedure of Example I to meniscus repair.

Articular cartilage was harvested from lamb joints, and the chondrocytes isolated as described in Example I above. Meniscus chips were harvested from the knees of lambs of the
10 same species.

Menisci were harvested from unrelated lambs, and each meniscus was divided into three parts. The vascularized portion was removed from the avascular zone of each part, and the menisci were devitalized using five freeze/thaw
15 cycles. A 4 mm-long buckle handle lesion (also called a fracture) was carved into each meniscus about 2 mm from the free margin of the avascular zone.

The devitalized chips were co-cultured with lamb chondrocytes as described in Example I. The menisci were
20 divided into four groups. In group A, a chip seeded with chondrocytes was sutured inside the buckle handle fracture of the meniscus. In group B, an unseeded chip was sutured onto the fracture. In group C, the meniscus fracture was sutured without a chip. In group D, the fracture was left
25 untreated (no suturing).

The fibrin glue gel described in Example I was then applied to the meniscus samples in each group so as to surround the samples with the gel. Each of two samples from each group was implanted into the subcutaneous pouch of a
30 nude mouse, totalling eight mice in all.

After 14 weeks, the meniscus samples were removed from the mice, grossly and histologically examined, and tested for cartilage repair as described in Example I. The samples

WO 99/22747

PCT/US98/23015

- 20 -

from group A kept their shape and were fully repaired, while the samples from groups B-D did not indicate any repair.

Example IV: Clinical Repair of Articular Cartilage

This example describes a prophetic protocol (adapted from Chu et al., supra) for repairing a full thickness articular cartilage defect in a knee joint of a human.

The surgical procedure entails entry of the knee joint through a standard midline incision. The damaged articular surface is removed with an osteotome in a rectangular pattern. Approximately 5 mm of subchondral bone is removed with a high-speed burr. The host bed is then measured.

A similarly sized and located allograft is removed from a fresh cadaver knee of a healthy donor. The cadaver knee matches the defective knee in size, as determined by the anteroposterior dimension of the tibial plateau on standard radiographs. The allograft subchondral bone is tailored with a burr to a thickness of 5 to 10 mm. Pulsatile lavage is used to flush out cellular elements from the marrow. A bonding composition containing fibrin gel and chondrocytes derived from the bone marrow of the patient (about 10^6 cells/ml) is applied to the host bed and the allograft at places where the two will contact. The allograft is then press-fitted into the host bed and positioned about 1 to 2 mm above the articular surface of the host bone. Resorbable pins are used for temporary internal fixation.

Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims.

Other aspects, advantages, and modifications are within the scope of the following claims.

WO 99/22747

PCT/US98/23015

- 21 -

What is claimed is:

1. A method of bonding a first cartilage piece and a second cartilage piece, the method comprising:
providing a bonding composition comprising
5 isolated chondrocytes mixed with a biological gel;
applying the composition to a surface of the first cartilage piece; and
contacting the surface with the second cartilage piece.
- 10 2. The method of claim 1, wherein the biological gel is fibrin gel.
3. The method of claim 1, wherein the first cartilage piece contains no viable endogenous chondrocytes.
4. The method of claim 1, wherein the second
15 cartilage piece is a defective part of a joint in a mammal.
5. The method of claim 4, wherein the biological gel is fibrin gel.
6. A method of bonding a first cartilage piece and a second cartilage piece, the method comprising:
20 providing a bonding composition comprising
isolated chondrocytes mixed with a biological gel;
holding the two cartilage pieces in apposition;
and
filling gaps between the two cartilage pieces with
25 the bonding composition.
7. The method of claim 6, wherein the biological gel is fibrin gel.

WO 99/22747

PCT/US98/23015

- 22 -

8. The method of claim 6, wherein the first cartilage piece contains no viable endogenous chondrocytes.

9. The method of claim 6, wherein the second cartilage piece is a defective part of a joint in a mammal.

5 10. The method of claim 9, wherein the biological gel is fibrin gel.

11. A method of bonding a first cartilage piece and a second cartilage piece, the method comprising:
 providing isolated chondrocytes;
10 contacting the chondrocytes with either or both of the cartilage pieces;
 applying a biological gel to a surface of the first cartilage piece; and
 contacting the surface with the second cartilage
15 piece, in the presence of the chondrocytes.

12. The method of claim 11, wherein the biological gel is fibrin gel.

13. The method of claim 11, wherein the cartilage piece that is contacted with the isolated chondrocytes
20 contains no viable endogenous chondrocytes.

14. The method of claim 11, wherein the second cartilage piece is a defective part of a joint in a mammal.

15. The method of claim 14, wherein the biological gel is fibrin gel.

25 16. A method of bonding a first cartilage piece and a second cartilage piece, the method comprising:

WO 99/22747

PCT/US98/23015

- 23 -

providing isolated chondrocytes;
contacting the chondrocytes with either or both of
the cartilage pieces;
holding the two cartilage pieces in apposition;
5 and
filling gaps between the two cartilage pieces with
a biological gel.

17. The method of claim 16, wherein the
biological gel is fibrin gel.

10 18. The method of claim 16, wherein the cartilage
piece that is contacted with the isolated chondrocytes
contains no viable endogenous chondrocytes.

19. The method of claim 16, wherein the second
cartilage piece is a defective part of a joint in a mammal.

15 20. The method of claim 19, wherein the
biological gel is fibrin gel.

21. A method of preparing a cartilage implant,
the method comprising:
providing isolated chondrocytes and a cartilage
20 piece;
incubating the chondrocytes with the cartilage
piece to produce an incubated cartilage piece; and
applying a biological gel to the incubated
cartilage piece to generate a cartilage implant.

25 22. The method of claim 21, wherein the
biological gel is fibrin gel.

23. The method of claim 21, wherein the cartilage
piece contains no viable endogenous chondrocytes.

WO 99/22747

PCT/US98/23015

- 24 -

24. The method of claim 22, wherein the cartilage piece is obtained from a mammal.



25. A cartilage implant comprising a cartilage piece and a bonding composition on a surface of the
5 cartilage piece, the bonding composition containing a biological gel and isolated chondrocytes.

26. A cartilage implant comprising a cartilage piece, a biological gel on a surface of the cartilage piece, and chondrocytes exogenously introduced to the cartilage
10 piece.

WO 99/22747

PCT/US98/23015


1/2



WO 99/22747

PCT/US98/23015

2/2



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/23015

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : Please See Extra Sheet. US CL : Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/548, 93.7, 94.64, 422; 530/381, 382; 435/214, 326, 395, 397, 402 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) USPATFULL, WPIDS, JAPIO, CA, SCISEARCH, MEDLINE, BIOSIS, EMBASE														
C. DOCUMENTS CONSIDERED TO BE RELEVANT														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X - Y	US 4,642,120 A (NEVO et al) 10 February 1987, see entire document.	1-10 ----- 11-26												
X - Y	US 5,549,904 A (JUERGENSEN et al) 27 August 1996, see entire document.	25-26 ----- 1-24												
X,P - Y,P	US 5,736,132 A (JUERGENSEN et al) 07 April 1998, see entire document.	25-26 ----- 1-24												
X - Y	US 5,631,011 A (WADSTROM) 20 May 1997, col. 6, lines 9-16.	25-26 ----- 1-24												
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*B* earlier document published on or after the international filing date</td> <td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*A* document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family													
O document referring to an oral disclosure, use, exhibition or other means														
P document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 04 JANUARY 1999		Date of mailing of the international search report 02 FEB 1999												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>Kristin Vidovich</i> KRISTIN VIDOVICH Telephone No. (703) 308-0196												

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/23015

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,658,343 A (HAUSELMANN et al) 19 August 1997, col. 1, lines 60-66, col. 4, lines 51-64.	1-26
X,P	US 5,759,190 A (VIBE-HANSEN et al) 02 June 1998, see entire document.	1-26
Y	US 5,842,477 A (NAUGHTON et al) 01 December 1998, see entire document.	1-26
Y	JURGENSEN, K. et al. A New Biological Glue for Cartilage-Cartilage Interfaces: Tissue Transglutaminase. The Journal of Bone and Joint Surgery. February 1997, Vol. 79-A, No. 2, pages 185-193, especially page 185.	1-26
Y	PITMAN, M.I. et al. The Use of Adhesives in Chondrocyte Transplantation Surgery: In-Vivo Studies. Bull. Hosp. JT Dis. Orthop. Inst. 1989, Vol. 49, No. 2, pages 213-220, see entire document.	1-26
Y	QUATELA, V.C. et al. Effects of Cyanoacrylate Tissue Adhesives on Cartilage Graft Viability. Laryngoscope. July 1993, Vol. 103, No. 7, pages 798-803, see entire document.	1-26
X - Y	HOMMINGA, G.N. et al. Chondrocyte Behavior in Fibrin Glue In Vitro. Acta Orthop. Scand. 1993, Vol. 64, No. 4, pages 441-445, see entire document.	1-24 ----- 25-26

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/23015

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

A61K 35/34, 35/14, 38/48; A01N 63/00; A61F 13/00; C12N 9/74, 5/00, 5/02, 5/06, 5/16

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

424/548, 93.7, 94.64, 422; 530/381, 382; 435/214, 326, 395, 397, 402